Entera Bio Ltd. (ENTX) Stock Price & Analysis
Entera Bio Ltd. (ENTX) rose 1.70% to USD 3 as of September 8, 2026 at 08:17 UTC, according to Nexqual real-time market data.
ENTX last closed at USD 3; the session ranged USD 2.88–3.14 on volume of 606,922 shares. Market capitalization is —, with a 52-week range of USD 0.91–4.2 (NCM). Source: Nexqual, September 8, 2026 at 08:17 UTC.
Key Statistics (as of September 8, 2026 at 08:17 UTC)
| Price | USD 3 |
|---|---|
| Change | ▲ 1.70% (up) |
| Previous Close | USD 3 |
| Open | USD 3 |
| Day Range | USD 2.88 – 3.14 |
| 52-Week Range | USD 0.91 – 4.2 |
| Volume | 606,922 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (ENTX)
Nexqual's technical model rates ENTX "BUY" based on 4 bullish and 1 bearish signals across 128 daily candles, as of September 8, 2026 at 08:17 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 56.38 (neutral) |
| vs SMA50 | Above (USD 2.55) |
| MACD | 0.11 (positive) |
Analyst Ratings (ENTX)
Wall Street analysts rate ENTX "None" based on 1 analysts, with a mean price target of USD 9 (range USD 9–9), per Nexqual as of September 8, 2026 at 08:17 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 9 |
| High Target | USD 9 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 1 / 0 / 0 |
From Entera Bio Ltd.'s Latest SEC 10-K Filing (filed 2026-03-27)
Key Strengths & Strategy (as disclosed to the SEC)
- All other provisions of the Patent Transfer Agreement remain in full force and effect.   Israeli Innovation Authority Grants   We have received grants of approximately $0.5 million from the IIA to partially fund our PTH research and development for Osteoporosis.  The grants are subject to certain requirements and restrictions under the Research Law.
Partnerships
- We intend to accelerate development and currently expect to submit an IND application to the FDA in late 2026.   80   EB618 Program (Oral GLP-1/Glucagon)   In September 2023, we entered into the 2023 Collaboration Agreement with OPKO Biologics.
- These data support the development of a once-daily oral PTH tablet for patients with hypoparathyroidism.   In February 2026, we announced the expansion of our collaboration with OPKO Biologics and OPKO to jointly advance this LA-PTH program.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VCNX | Vaccinex, Inc. | USD 0.75 | ▼ 25% |
| ATHE | Alterity Therapeutics Limited | USD 4.54 | ▲ 0.44% |
| ENVB | Enveric Biosciences, Inc. | USD 1.39 | ▼ 3.47% |
| IMMP | Immutep Limited | USD 0.36 | ▼ 3.97% |
| ADIL | Adial Pharmaceuticals, Inc | USD 7.12 | ▲ 12.66% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 08:17 UTC. This page is informational and not investment advice.